Posts tagged “BDSI”

Updated October 21, 2013

Premium Lock BioDelivery Sciences names new chief financial officer

BDSI The Raleigh-based firm says its current CFO Jim McNulty will assume a new role as senior vice president for finance and treasurer.

October 9, 2013

Premium Lock BioDelivery Sciences' opioid treatment could win FDA approval in '14

The Raleigh-based drug delivery technology firm projects sales of up to $250 million if the opioid dependence treatment wins FDA approval next year.

How BDSI technology works How BDSI technology works

August 15, 2013

Premium Lock BDSI makes drug pipeline progress but reports $13.1M 2Q loss

BDSI BDSI swings to a $13.1 million loss in the second quarter, a change that reflects the $15 million milestone payment the company recorded in the second quarter of 2012.

August 1, 2013

Premium Lock Opioid dependence treatment from BDSI filed for FDA approval

BDSI's drug pipeline With Bunavail, BDSI aims to secure FDA approval on the first opioid dependence treatment that delivers abuse deterrents through the lining of the cheek.

July 29, 2013

Premium Lock BioDelivery Sciences' pain killer wins OK in Taiwan

BDSI The approval triggers a $300,000 milestone payment and future royalties from BDSI's partner in the island nation.

July 12, 2013

Premium Lock Drug delivery and more: BDSI flashes potential of revived drug pipeline

BioDelivery Sciences International's current pipeline reflects a shift in direction and a effort to stretch beyond the drug-delivery technology that was the initial focus for the company. Learn more about BDSI's strategy.

BDSI's drug pipeline BDSI's drug pipeline

July 8, 2013

Premium Lock BDSI lands $20M loan to support drug application, clinical trials

BDSI The $20 million loan shores up BDSI's finances as it prepares a new drug application for Bunavail and finishes phase III trials on a chronic pain drug candidate.

Updated March 26, 2013

Premium Lock Raleigh drug firm BDSI pays up to $40M for pain drug candidate

BDSI BioDelivery Sciences strikes a deal to license a potential treatment for diabetic neuropathy with privately held Arcion Therapeutics. The mix of stock and cash could total nearly $40 million if the drug wins approval.

January 22, 2013

Premium Lock Raleigh drug firm BDSI reports positive results of opioid dependence treatment

BDSI BioDelivery Sciences International says its proposed alternative treatment for opioid-dependent patients is safe and is safely tolerated when users of another product are switched.

November 29, 2012

Premium Lock Raleigh-based BDSI raises $40M in stock sale

Institutional investors have agreed to buy nearly 6.8 million of BDSI common shares and 2.7 million of newley designated Series A convertible preferred stock for an aggregate price of $4.21 each.

BDSI's product pipeline BDSI's product pipeline

September 14, 2012

Premium Lock SciQuest grants; Lenovo film winners; Quintiles deal; BDSI good news; Gentris expands

Bulldog Inside the Bulldog Blog: SciQuest picks five charitable grant winners; Lenovo names winners in film contest; Quintiles lands deal in Mexico; BDSI reports good news on drug; Gentris expands headquarters.

August 20, 2012

Premium Lock In the news: AT&T, FaceTime plan, IBM, Epic investor, BDSI

Bulldog Inside the Bulldog Blog: AT&T may stop discounted table sales; groups protest AT&T FaceTime plan; IBM loses top outsourcer; investor in Epic Games eyes more growth; BDSI completes trial enrollment.

August 6, 2012

Premium Lock BioDelivery Sciences moves closer to $30M in milestone payments

The Raleigh-based firm also terminates its vice president for business and strategic development "without cause."

BDSI's product pipeline BDSI's product pipeline

May 21, 2012

Premium Lock BioDelivery Sciences receives $2.5M milestone payment

BDSI The Raleigh-based drug development firm will receive another $2.5 million from its partner Meda when its breakthrough pain reliever goes on sale in Europe.

April 13, 2012

Premium Lock Raleigh firm BDSI targets growing drug abuse, addiction markets

BioDelivery Sciences plans to file a new drug application for its opioid dependence treatment BEMA Buprenorphine in the first half of 2013.

How BDSI technology works How BDSI technology works

Updated March 13, 2012

Premium Lock FDA concerns lead to delay in BDSI cancer drug relaunch

How BDSI technology works Over Onsolis' two-year shelf life, the product's pink appearance can fade. The FDA told the Raleigh company that the color change could confuse patients and the agency is directing BDSI to make formulation changes.

March 8, 2012

Premium Lock BioDelivery Sciences makes clean sweep in patent fight

How BDSI technology works The U.S. Patent and Trademark Office has rejected all claims made by MonoSol Rx in the third MonoSol patent that the New Jersey company alleged BDSI had infringed. In total, MonoSol had made 222 claims covering three of its patents.

Updated March 6, 2012

Premium Lock Triangle news:; BioDelivery Sciences; SAS; Precision BioSciences; Novella Clinical; SlickEdit

Tech briefs division Inetwork expands management team; BDSI says it prevails in patent fight; SAS makes knowledge management firm list; Precision files patent suit; Noval Clinical division adds new exec; SlickEdit to tout software to gamers.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith